The FDA recently approved a 7.5-mg formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine mesylate for the treatment of hot flashes.   It will be marketed under the name of Brisdelle.

It should be noted that while not yet approved by the FDA for this indication, other SSRIs and SNRIs (such as Effexor) may be as effective as Brisdelle.  Importantly, paroxetine may reduce the efficacy of tamoxifen; Brisdelle should therefore not be used in women taking tamoxifen.

Read More on Medscape (free subscription)

Ruta Nonacs, MD PhD

Related Posts